Rosen Quoted on Research Firm Asking FDA to Clear Path for Generic Fosamax

03 July 2014 Law360 News


Partner David Rosen was quoted in a Law360 article published on July 3, 2014, titled “Research Firm Asks FDA to Clear Path for Generic Fosamax.” The article discussed a citizen petition made by the research firm Clinipace Worldwide asking the U.S. Food and Drug Administration to issue a finding that Merck & Co. did not discontinue the osteoporosis drug Fosamax for health and safety reasons. Rosen was quoted saying, “There have been relatively few instances where the FDA has withdrawn the reference listed drug for reasons related to safety or effectiveness.”

Related Services


DOL Rolls Back Trump Administration’s Independent Contractor Rule
05 May 2021
Labor & Employment Law Perspectives
190 Across the Finish Line: CFTC Adopts New Bankruptcy Rules for FCMS and DCOS
05 May 2021
The Journal on the Law of Investment & Risk Management Products, Futures & Derivatives Law Report
Understanding SPACs' Hidden Capital Costs
05 May 2021
The Export Import Bank of the United States: Priorities and Programs Supporting U.S. Businesses and Jobs
04 May 2021
Manufacturing Industry Advisor
Home Care 100
27-30 June 2021
Marco Island, FL
2021 AANP National Conference
15 June - 31 August 2021
Virtual Conference
HCCA Orange County Regional Healthcare Compliance Conference
11 June 2021
Virtual Conference
Rx Pricing and Reimbursement Summit
24-25 May 2021
Virtual Conference